2-(6-Methoxy-2,3-dihydro-1-benzofuran-3-yl)acetic acid | 93198-72-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 香豆素
• 英文名称: 2-(6-Methoxy-2,3-dihydro-1-benzofuran-3-yl)acetic acid
• CAS: 93198-72-2
• 化学式: C₁₁H₁₂O₄
• 分子量: 208.214
• InChiKey: UPXQPBXFERQVDB-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.2
• 重原子数：
  15
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.36
• 拓扑面积：
  55.8
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  methyl 2'-hydroxy-4'-methoxycinnamate 以 二甲基亚砜 为溶剂， 反应 28.0h， 生成 2-(6-Methoxy-2,3-dihydro-1-benzofuran-3-yl)acetic acid
  参考文献：
  名称：

  Bravo, Pierfrancesco; Gentile, Anna; Ticozzi, Calimero, Gazzetta Chimica Italiana, 1984, vol. 114, # 3/4, p. 89 - 92

  摘要：

  DOI：

文献信息

• FUSED CYCLIC COMPOUNDS
  申请人：Yasuma Tsuneo

  公开号：US20100004312A1

  公开（公告）日：2010-01-07

  The present invention provides a compound represented by the formula (I): wherein each symbol is as defined in the description, or a salt thereof. The compound or a salt thereof or a prodrug thereof has a GPR40 receptor function modulating action and is useful as an insulin secretagogue or an agent for the prophylaxis or treatment of diabetes and the like.

  本发明提供一种化合物，其表示为公式（I）：其中每个符号如描述中所定义，或其盐。该化合物或其盐或其前药具有GPR40受体功能调节作用，并可用作胰岛素分泌剂或用于预防或治疗糖尿病等药物。
• Fused cyclic compounds
  申请人：Yasuma Tsuneo

  公开号：US20100197761A1

  公开（公告）日：2010-08-05

  The present invention provides a compound represented by the formula (I): wherein each symbol is as defined in the description, or a salt thereof. The compound or a salt thereof or a prodrug thereof has a GPR40 receptor function modulating action and is useful as an insulin secretagogue or an agent for the prophylaxis or treatment of diabetes and the like.

  本发明提供一种化合物，其化学式表示为（I）：其中每个符号如描述中所定义，或其盐。该化合物或其盐或其前药具有GPR40受体功能调节作用，并且可用作胰岛素分泌剂或预防或治疗糖尿病等疾病的药物。
• 3-Aminomethyl derivatives of indane, indoline and dihydrobenzofurane and dihydrobenzothiophene
  申请人：H. LUNDBECK A/S

  公开号：EP0281261A2

  公开（公告）日：1988-09-07

  Indane-, dihydrobenzofurane-, dihydrobenzothiophene-, and indoline- derivatives of the following formula: wherein X, R¹, R², R³ and R⁴ are as defined in Claim 1, are effective at presynaptic DA receptors, or both at pre- and postsynaptic DA receptors, indicating usefulness in the treatment of disorders of the central nervous system (CNS) such as schizophrenia or Parkinson's disease. The 1-aminomethyl derivatives of Formula I exist as optical isomers, and the useful effects are often found in the single enantiomers to a different degree. A method for the preparation of compounds of Formula I is described.

  下式中的茚满-、二氢苯并呋喃-、二氢苯并噻吩-和吲哚啉-衍生物： 其中X、R¹、R²、R³和R⁴如权利要求1中所定义，对突触前DA受体有效，或对突触前和突触后DA受体均有效，表明在治疗精神分裂症或帕金森病等中枢神经系统（CNS）疾病方面有用。 式I的1-氨基甲基衍生物以光学异构体形式存在，其有用的效果通常在单一对映体中以不同程度存在。 描述了一种制备式I化合物的方法。
• Fused cyclic compounds as GPR40 receptor modulators
  申请人：Takeda Pharmaceutical Company Limited

  公开号：EP2248812A2

  公开（公告）日：2010-11-10

  The present invention provides a pharmaceutical composition comprising a compound represented by the formula (I): wherein each symbol is as defined in the description, or a salt thereof, in combination with a dipeptidyl peptidase IV inhibitor, an insulin preparation, a PPAR function modulator, an α-glucosidase inhibitor, a biguanide, a sulfonylurea, mitiglinide or calcium salt hydrate thereof or nateglinide.

  本发明提供了一种药物组合物，其中包含由式 (I) 代表的化合物： 其中各符号如描述中所定义，或其盐与二肽基肽酶 IV 抑制剂、胰岛素制剂、PPAR 功能调节剂、α-葡萄糖苷酶抑制剂、双胍类、磺酰脲类、米格列奈或其钙盐水合物或纳格列奈联合使用。
• FUSED CYCLIC COMPOUNDS AS GPR40 RECEPTOR MODULATORS
  申请人：Takeda Pharmaceutical Company Limited

  公开号：EP2248812B1

  公开（公告）日：2013-12-25